A mouse model for HBV immunotolerance and immunotherapy

Cellular and Molecular Immunology

Volumn 11, Issue 1, 2014, Pages 71-78

  Yang, Dan ^a,b   Liu, Longchao ^a,b   Zhu, Danming ^a   Peng, Hua ^a   Su, Lishan ^c   Fu, Yang Xin ^a,d   Zhang, Liguo ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

AAV vector; HBV; Immunotherapy; Immunotolerance; Mouse model

Indexed keywords

ALUMINUM; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PARVOVIRUS VECTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; HEPATITIS B; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION PREVENTION; MALE; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; VACCINATION; VACCINE FAILURE; VIRAL CLEARANCE; VIREMIA; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; BLOTTING, WESTERN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VIREMIA;

EID: 84891757964     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.43     Document Type: Article

References (35)

1. World Health Organization. Hepatitis B. Fact sheet. Geneva: SWHO, 2012. Available from: http://www.who.int/mediacentre/factsheets/fs204/en. Accessed on May 10th, 2013.
2. Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012; 142: 1360-1368.e1.
3. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25: 19-25.
4. Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006; 5: 707-716.
5. Schirmbeck R, Wild J, Stober D, Blum HE, Chisari FV, Geissler M et al. Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen. J Immunol 2000; 164: 4235-4243.
6. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 6909-6913.
7. Wirth S, Guidotti LG, Ando K, Schlicht HJ, Chisari FV. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. J Immunol 1995; 154: 2504-2515.
8. Loirat D, Mancini-Bourgine M, Abastado JP, Michel ML. HBsAg/HLAA2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. Int Immunol 2003; 15: 1125-1136.
9. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002; 99: 13825-13830.
10. Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 2006; 103: 17862-17867.
11. Huang LR, Gäbel YA, Graf S, Arzberger S, Kurts C, Heikenwalder M et al. Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology 2012; 142: 1447-1450.e3.
12. Dong X, Yu CJ, Wang G, Tian WH, Lu Y, Zhang FW et al. Establishment of hepatitis B virus(HBV) chronic infection mouse model by in vivo transduction with a recombinant adeno-associated virus 8 carrying 1.3 copies of HBV genome(rAAV8-1.3HBV). Chin J Virol 2010; 26: 425-431.
13. Wang G, Dong XY, Tian WH, Yu CJ, Zheng G, Gao J et al. Study on the differences of two mouse models of hepatitis B virus infection by transduction with rAAV8-1.3HBV. Chin J Virol 2012; 28: 541-547.
14. Wang G, Wang G, Dong X, Tian W, Yuchi J, Wei G et al. Anti-HBV effect of nucleotide analogues on mouse model of chronic HBV infection mediated by recombinant adeno-associated virus 8. Chin J Biotechnol 2013; 29: 95-106. Chinese.
15. Wang SH, Yeh SH, Lin WH, Yeh KH, Yuan Q, Xia NS et al. Estrogen receptor alpha represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4alpha. Gastroenterology 2012; 142: 989-998.e4.
16. Tian Y, Kuo CF, Chen WL, Ou JH. Enhancement of hepatitis B virus replication by androgen and its receptor in mice. J Virol 2012; 86: 1904-1910.
17. Andres LL, Sawhney VK, Scullard GH, Smith JL, Merigan TC, Robinson WS et al. Dane particle DNA polymerase and HBeAg: impact on clinical, laboratory, and histologic findings in hepatitis B-associated chronic liver disease. Hepatology 1981; 1: 583-585.
18. Nguyen T, Sawhney VK, Scullard GH, Smith JL, Merigan TC, Robinson WS et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-513.
19. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
20. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
21. Wijaya I, Hasan I. Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent. Acta Med Indones 2013; 45: 61-66.
22. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 2001; 11: 287-299.
23. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17: 1531-1537.
24. Dion S, Bourgine M, Godon O, Levillayer F, Michel ML. Adenoassociated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLADR1 molecules. J Virol 2013; 87: 5554-5563.
25. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54: 1286-1296.
26. Huang YH, Fang CC, Tsuneyama K, Chou HY, Pan WY, Shih YM et al. A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery. Int J Oncol 2011; 39: 1511-1519.
27. Huang YH, Fang CC, Tsuneyama K, Chou HY, Pan WY, Shih YM et al. A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery. Int J Oncol 2011; 39: 1511-1519.
28. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al. A Tolllike receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
29. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
30. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73: 329-368.
31. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24: 693-701.
32. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
33. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61: 195-204.
34. Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvantcontaining vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 2011; 10: 417-427.
35. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011; 10: 499-511.